Paper42636799
Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.
Wang S and 35 others. Cell Rep Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma. Papers, record 42636799. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42636799
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Cell-Free Nucleic Acids | Major topic |
| Genomics | Major topic |
| Humans | |
| Prognosis | |
| Female | |
| Male | |
| Middle Aged | |
| Aged | |
| Whole Genome Sequencing | |
| Biomarkers, Tumor |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40833414 | Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40833414 | PubMed |
| 2 | 34932792 | Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. | Blood | 2022 | https://conductscience.org/library/papers/34932792 | PubMed |
| 3 | 33122345 | Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33122345 | PubMed |
| 4 | 20435884 | Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. | Blood | 2010 | https://conductscience.org/library/papers/20435884 | PubMed |
| 5 | 41428995 | Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/41428995 | PubMed |
| 6 | 30125215 | Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30125215 | PubMed |
| 7 | 28774879 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. | Blood | 2017 | https://conductscience.org/library/papers/28774879 | PubMed |
| 8 | 28668386 | Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28668386 | PubMed |
| 9 | 29713087 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. | Nat Med | 2018 | https://conductscience.org/library/papers/29713087 | PubMed |
| 10 | 32554709 | ctDNA monitoring using patient-specific sequencing and integration of variant reads. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32554709 | PubMed |
| 11 | 35732829 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732829 | PubMed |
| 12 | 34050156 | Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. | Nat Commun | 2021 | https://conductscience.org/library/papers/34050156 | PubMed |
| 13 | 37001036 | Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. | Blood | 2023 | https://conductscience.org/library/papers/37001036 | PubMed |
| 14 | 40055810 | Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40055810 | PubMed |
| 15 | 42215793 | Advancing the applications of liquid biopsies in oncology. | Nat Rev Genet | 2026 | https://conductscience.org/library/papers/42215793 | PubMed |
| 16 | 23859481 | Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. | Eur J Haematol | 2013 | https://conductscience.org/library/papers/23859481 | PubMed |
| 17 | 29109393 | Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. | Nat Commun | 2017 | https://conductscience.org/library/papers/29109393 | PubMed |
| 18 | 20080505 | Fast and accurate long-read alignment with Burrows-Wheeler transform. | Bioinformatics | 2010 | https://conductscience.org/library/papers/20080505 | PubMed |
| 19 | 39089812 | International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation. | J Nucl Med | 2024 | https://conductscience.org/library/papers/39089812 | PubMed |
| 20 | 20212248 | Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20212248 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42887064 | Cell-free DNA fragmentomics and epigenomic profiling in hematologic malignancies: current evidence, translational limitations, and future directions. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42887064 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42636799
GET https://conductscience.org/api/papers/v1/42636799/authors?page=2